You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 昊海生物科技(6826.HK)反彈逾8% 治療細菌性結膜炎滴眼液獲內地批准上市
格隆匯 03-11 11:14
格隆匯3月11日丨昊海生物科技(6826.HK)反彈拉昇至8.2%,近期自高點最高回撤30%。現報56.1港元,總市值99.4億港元。昊海生物科技10日公佈,公司研製的鹽酸莫西沙星滴眼液用於治療細菌性結膜炎的上市註冊申請,獲國家藥品監督管理局批准,公司為產品上市許可持有人,上海信誼金朱藥業作為產品受託生產企業。本產品獲批上市標誌着公司具備了在國內市場銷售該藥品的資格,豐富了公司的產品線,有助於提升公司產品的市場競爭力,對公司經營發展具有一定積極作用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account